Copyright
©The Author(s) 2005.
World J Gastroenterol. Aug 7, 2005; 11(29): 4484-4489
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Table 3 Rate (number responding/total treated) of patients with negative viremia after the 24-wk post-therapy follow-up according to genotype
| 1 | Non-1 | Notdetermined | |
| r-hIFN β-1a | 12.90% | 35.00% | |
| (4/31) | (7/20) | – | |
| r-hIFN β-1a + ribavirin | 12.10% | 52.90% | |
| (4/33) | (9/17) | (1/1) |
- Citation: Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489
- URL: https://www.wjgnet.com/1007-9327/full/v11/i29/4484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i29.4484